 | • レポートコード：MRC2303G038 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の心臓安全サービス市場規模が、予測期間中（2022年-2027年）CAGR 9％で増加すると推測されています。本書では、心臓安全サービスの世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（統合型サービス、独立型サービス）分析、サービス種類別（心電図/ホルター測定、血圧測定、心血管系イメージング、QT評価試験）分析、エンドユーザー別（医薬品・バイオ医薬品企業、受託研究機関）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Biotrial、Bioclinica、Ncardia AG、Richmond Pharmacology、PhysioStim、BioTelemetryなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の心臓安全サービス市場規模：種類別 - 統合型サービスの市場規模 - 独立型サービスの市場規模 ・世界の心臓安全サービス市場規模：サービス種類別 - 心電図/ホルター測定における市場規模 - 血圧測定における市場規模 - 心血管系イメージングにおける市場規模 - QT評価試験における市場規模 ・世界の心臓安全サービス市場規模：エンドユーザー別 - 医薬品・バイオ医薬品企業における市場規模 - 受託研究機関における市場規模 ・世界の心臓安全サービス市場規模：地域別 - 北米の心臓安全サービス市場規模 アメリカの心臓安全サービス市場規模 カナダの心臓安全サービス市場規模 メキシコの心臓安全サービス市場規模 … - ヨーロッパの心臓安全サービス市場規模 ドイツの心臓安全サービス市場規模 イギリスの心臓安全サービス市場規模 フランスの心臓安全サービス市場規模 … - アジア太平洋の心臓安全サービス市場規模 中国の心臓安全サービス市場規模 日本の心臓安全サービス市場規模 インドの心臓安全サービス市場規模 … - 南米/中東の心臓安全サービス市場規模 ブラジルの心臓安全サービス市場規模 アルゼンチンの心臓安全サービス市場規模 サウジアラビアの心臓安全サービス市場規模 ・競争状況 ・市場機会・将来動向 |
The cardiac safety service market is expected to register a CAGR of 9% during the forecast period (2022-2027).
The COVID-19 pandemic has imposed a high burden on the healthcare industry, increasing its focus on providing better healthcare facilities, monitoring devices, services, and teleconsultation. According to the World Health Organization, 2020, more than half (53%) of the countries surveyed have partially or completely disrupted services for hypertension treatment and 31% for cardiovascular emergencies. The emergence of COVID-19 has compelled the government and companies to invest a huge amount of money in research and development to provide better treatments, drugs, and services to patients globally. For instance, it has been found that COVID-19 has increased the risk of all types of cardiovascular ailments. According to the National Center for Biotechnology Information, 2021, evidence of acute cardiac compromise was observed in COVID-19 patients, which includes acute heart failure (3%–33%), myocardial ischemia or infarction (0.9%–11%), and arrhythmias (9%–17%). There has been an increased number of cardiovascular deaths observed in the country during the pandemic. For instance, New York experienced the largest relative increase in deaths due to ischemic heart disease (139%) and hypertensive diseases (164%) during the pandemic, as reported by the American College of Cardiology.
The growth of the cardiac safety service market is mainly due to the rising prevalence of cardiovascular diseases and growing awareness among people regarding cardiac problems and chronic heart diseases. According to the National Center for Biotechnology Information, 2021, around 64.3 million people are suffering from heart failure worldwide. The prevalence rate of heart failure in the United States is 6 million, which is 1.8% of its total population. In Canada, the prevalence rate is 1,5% to 1.9%, and in Europe, the prevalence rate of heart failure is estimated to be 1% to 2% in 2021, as reported by the American Heart Association. Additionally, the increasing R&D expenditure by the healthcare industries and outsourcing R&D activities are some factors boosting the growth of the market. Modern technology has brought solutions to help monitor and improve cardiovascular health. For instance, cardiology and radiology equipment now use artificial intelligence and machines, which help by locating potential problems in the heart and blood vessels for the cardiologist to review. The increasing number of cardiovascular diseases among the population tends to increase the use of cardiac safety services in developed countries.
However, the huge cost of services and lack of skilled persons are likely to hinder the market growth.
Cardiac Safety Service Market Trends
The ECG Holter Measurement Service Segment Dominates the Market
The ECG Holter service is expected to dominate the market in the forecast period.
The growth in this segment is mainly attributed to a rise in the geriatric population and the increasing prevalence of cardiovascular diseases. According to the data published by Health System Tracker, 2022, it has been observed that heart disease is the number one leading cause of death in the United States. The World Heart Federation has predicted more than 23 million CVD-related deaths per year by 2030. Owing to these factors, there is a need for continuous heart rate monitoring and immediate heartbeat detection devices. ECG monitoring devices have been used in the past years in the healthcare system to detect any abnormality in the functioning of the heart. With the advancement of technology, new ECG Holter measurement devices have been introduced. A Holter monitor is a battery-operated portable ECG device that can be worn by a patient for a duration of 24 to 48 hours and records heart activity (electrocardiogram) continuously and monitors the heart rhythm. This portable device provides several advantages over the traditional ECG devices, such as fewer leads, and the patient is free to move and go around their usual daily routines, which has increased its usage among patients and physicians. Various wearable ECG devices have been introduced in the market that have ECG/EKG sensors to monitor heart health, such as Apple Watch, AliveCor’s KardiaBand, and the Withings ScanWatch. The Apple Watch 4 and up and the AliveCor Kardia devices all have been tested and approved by the Food and Drug Administration to detect atrial fibrillation, which is a heart condition that can lead to heart failure, strokes, and even dementia.
These advanced ECG-Holter measurement devices offer a lucrative opportunity for the growth of the cardiac safety services market.
North America Dominates the Market, and It is Expected to do the Same During the Forecast Period
North America is expected to account for a major share of cardiac safety services during the forecast period, owing to the rise in the number of geriatric patients and the high prevalence of cardiovascular diseases. According to the data published by the American Heart Association, 2020, it has been found that approximately 605,000 new heart attack cases and 200,000 recurrent heart attacks have been recorded each year in the United States. COVID-19 has increased the risk of heart diseases among people. For instance, US veterans who had COVID-19 faced a 72% higher risk of heart failure after 12 months. According to the data published by Nature Medicine, 2022, titled ‘Long Covid’ may worsen risk of heart diseases”, it has been found that 1.7% of COVID-19 patients in the United States are more likely to develop cardiovascular diseases or dysregulated heart rhythm, and 2.39% are likely to have blood clots in the blood vessels.
In addition, the advanced healthcare system, increasing awareness among people of preventive measures for cardiovascular diseases instead of treatment, healthcare campaigns, and government investments in the healthcare system and providing services are likely to boost the growth of the market in the region. There are several leading cardiac event monitoring companies in the United States that provide various forms of long-term cardiac monitoring, such as Applied Cardiac Systems (ACS) and BioTelemetry, which are formed from acquisitions of several leading monitoring companies and Spacelabs.
Cardiac Safety Service Market Competitor Analysis
The cardiac safety service market is highly fragmented, with the presence of a large number of players in the market. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions to increase their footprints in this market. Some of the major players of the market include Biotrial, Banook Group, Bioclinica, BioTelemetry, and Ncardia AG.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Prevalence of Cardiovascular Diseases
4.2.2 Rising Focus on Developing Personalized Medicines
4.2.3 Growth in the Analysis and Development Investment in Pharma
4.3 Market Restraints
4.3.1 High Cost of Cardiac Safety Evaluation
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Type
5.1.1 Integrated Services
5.1.2 Stand-alone Services
5.2 Service Type
5.2.1 ECG/Holter Measurement
5.2.2 Blood Pressure Measurement
5.2.3 Cardiovascular Imaging
5.2.4 Thorough QT Studies
5.3 End User
5.3.1 Pharmaceutical and Biopharmaceutical Companies
5.3.2 Contract Research Organizations
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biotrial
6.1.2 Bioclinica
6.1.3 Ncardia AG
6.1.4 Richmond Pharmacology
6.1.5 PhysioStim
6.1.6 BioTelemetry
7 MARKET OPPORTUNITIES AND FUTURE TRENDS